This study was designed to explore the relationship between the creatinine-to-cystatin C ratio (CCR) and 1-year all-cause mortality in breast cancer patients, while evaluating the clinical validity of CCR as an independent serological prognostic marker for 1-year mortality risk. Here, CST3 is linked to breast carcinoma.